05.09.16
Juniper Pharma Services, a subsidiary of Juniper Pharmaceuticals, is investing in its spray drying capabilities. The contract development and manufacturing organization (CDMO) has placed an order for a PSD-1 spray dryer, which is manufactured by GEA Niro.
To date, the company has provided bench-top scale spray drying to support clients’ early phase proof-of-concept trials. This investment will allow Juniper Pharma Services to scale-up the process to support later clinical phases and niche commercial scale.
Designed for both aqueous- and solvent-based formulations, spray drying forms a key part of the company’s broad enabling technologies screening platform. It extends the CDMO’s current spray drying capabilities by around 10 times, and will mimic the processing performance and controls of full-scale production equipment.
“This order forms part of a wider investment program in our business that will see a significant step-up in our development and manufacturing capabilities over the next year,” said Claire Madden-Smith, senior vice president, Juniper Pharma Services. “The decision to purchase this spray dryer is simply about scale and expanding the support we can deliver to help further our clients' development programs. It also demonstrates our commitment to helping drug developers with both simple and complex formulation challenges.”
The company expects the new equipment to be operational by Q4 2016.
The PSD-1 will allow Juniper Pharma Services to provide drug developers with particle engineering options and making amorphous materials to help with solubility and bioavailability challenges.
To date, the company has provided bench-top scale spray drying to support clients’ early phase proof-of-concept trials. This investment will allow Juniper Pharma Services to scale-up the process to support later clinical phases and niche commercial scale.
Designed for both aqueous- and solvent-based formulations, spray drying forms a key part of the company’s broad enabling technologies screening platform. It extends the CDMO’s current spray drying capabilities by around 10 times, and will mimic the processing performance and controls of full-scale production equipment.
“This order forms part of a wider investment program in our business that will see a significant step-up in our development and manufacturing capabilities over the next year,” said Claire Madden-Smith, senior vice president, Juniper Pharma Services. “The decision to purchase this spray dryer is simply about scale and expanding the support we can deliver to help further our clients' development programs. It also demonstrates our commitment to helping drug developers with both simple and complex formulation challenges.”
The company expects the new equipment to be operational by Q4 2016.
The PSD-1 will allow Juniper Pharma Services to provide drug developers with particle engineering options and making amorphous materials to help with solubility and bioavailability challenges.